BioCentury | Oct 5, 2015
Tools & Techniques

J&J intercepts Nextera

...disease interception deals with a T cell focus. In 2013 Janssen partnered with Australian biotech Dendright Pty. Ltd....
...not included in the Janssen deal. Companies and Institutions Mentioned Atreca Inc., Redwood City, Calif. Dendright Pty. Ltd....
BioCentury | Jul 9, 2015
Strategy

The priority of proximity

...door to everybody and anybody who wants to collaborate with us." Companies and Institutions Mentioned Dendright Pty. Ltd....
...using components of spider venom. The next year, Janssen Biotech Inc. partnered with Uniquest spinout Dendright Pty. Ltd....
BioCentury | Mar 2, 2015
Product Development

Prevention by the pound

...of the molecular targets of an immune response. The immunology group also is collaborating with Dendright Pty. Ltd....
...The liposome encapsulates the NF-kB inhibitor curcumin and a disease-specific antigen. Under a 2013 deal, Dendright...
...already been some discussion," he said. Companies and Institutions Mentioned Atreca Inc., San Carlos, Calif. Dendright Pty. Ltd....
BioCentury | Aug 19, 2013
Company News

Dendright, J&J deal

...develop and commercialize Dendright's RA-Curcusome program, which is in preclinical testing to treat rheumatoid arthritis. Dendright...
...of NF-kappa B (NF-kB) and the protein v-rel reticuloendotheliosis viral oncogene homolog B (RELB) . Dendright's...
...Dendright will receive an option payment and will be eligible for milestones and tiered royalties. Dendright...
BioCentury | Jan 23, 2012
Company News

Dendright Pty. Ltd., J&J autoimmune news

...unit of Johnson & Johnson and received a seed grant to fund preclinical development of Dendright's...
...of NF-kappa B (NF-kB) and the protein v-rel reticuloendotheliosis viral oncogene homolog B (RELB) . Dendright...
...and an antigen to silence T cells in an "antigen-specific manner." Details were not disclosed. Dendright...
Items per page:
1 - 5 of 5
BioCentury | Oct 5, 2015
Tools & Techniques

J&J intercepts Nextera

...disease interception deals with a T cell focus. In 2013 Janssen partnered with Australian biotech Dendright Pty. Ltd....
...not included in the Janssen deal. Companies and Institutions Mentioned Atreca Inc., Redwood City, Calif. Dendright Pty. Ltd....
BioCentury | Jul 9, 2015
Strategy

The priority of proximity

...door to everybody and anybody who wants to collaborate with us." Companies and Institutions Mentioned Dendright Pty. Ltd....
...using components of spider venom. The next year, Janssen Biotech Inc. partnered with Uniquest spinout Dendright Pty. Ltd....
BioCentury | Mar 2, 2015
Product Development

Prevention by the pound

...of the molecular targets of an immune response. The immunology group also is collaborating with Dendright Pty. Ltd....
...The liposome encapsulates the NF-kB inhibitor curcumin and a disease-specific antigen. Under a 2013 deal, Dendright...
...already been some discussion," he said. Companies and Institutions Mentioned Atreca Inc., San Carlos, Calif. Dendright Pty. Ltd....
BioCentury | Aug 19, 2013
Company News

Dendright, J&J deal

...develop and commercialize Dendright's RA-Curcusome program, which is in preclinical testing to treat rheumatoid arthritis. Dendright...
...of NF-kappa B (NF-kB) and the protein v-rel reticuloendotheliosis viral oncogene homolog B (RELB) . Dendright's...
...Dendright will receive an option payment and will be eligible for milestones and tiered royalties. Dendright...
BioCentury | Jan 23, 2012
Company News

Dendright Pty. Ltd., J&J autoimmune news

...unit of Johnson & Johnson and received a seed grant to fund preclinical development of Dendright's...
...of NF-kappa B (NF-kB) and the protein v-rel reticuloendotheliosis viral oncogene homolog B (RELB) . Dendright...
...and an antigen to silence T cells in an "antigen-specific manner." Details were not disclosed. Dendright...
Items per page:
1 - 5 of 5